Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase 1 2Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 108Ovarian Neoplasms 64Neoplasms 61Fallopian Tube Neoplasms 40Lung Neoplasms 37Breast Neoplasms 33Neoplasm Metastasis 25Carcinoma, Ovarian Epithelial 25Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 20Esophageal Neoplasms 19Endometrial Neoplasms 19Colorectal Neoplasms 15Advanced Solid Tumors 14Squamous Cell Carcinoma of Head and Neck 13Lymphoma, Large B-Cell, Diffuse 13Unspecified Adult Solid Tumor, Protocol Specific 12Stomach Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Astrocytoma 10Neuroblastoma 9Medulloblastoma 9Head and Neck Neoplasms 9Carcinoma 9Urinary Bladder Neoplasms 8Solid Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

pembrolizumab 11Nivolumab 7Sunitinib 6Cyclophosphamide 6aldesleukin 5Sorafenib 5Everolimus 5temsirolimus 4belzutifan 4atezolizumab 4Ipilimumab 4fludarabine 3cabozantinib 3Interferon-alpha 3Gene Expression Profiling 3Fluorouracil 3Docetaxel 3Cetuximab 3Busulfan 3valspodar 2sargramostim 2perifosine 2pazopanib 2ixabepilone 2entinostat 2ciforadenant 2belinostat 2Thiotepa 2Temozolomide 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Kidney Neoplasms × Carboplatin × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT00303940 2012-03-15

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Familial ependymoma, Ovarian Germ Cell Cancer, Astrocytoma, Kidney Neoplasms, Liver Neoplasms, Medulloblastoma, Wilms Tumor, Neuroblastoma, Oligodendroglioma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡